Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Pharmacol ; 154(6): 1308-17, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18516076

ABSTRACT

BACKGROUND AND PURPOSE: Eosinophil peroxidase (EPO) catalyses the formation of oxidants implicated in the pathogenesis of various respiratory diseases including allergy and asthma. Mechanisms for inhibiting EPO, once released, are poorly understood. The aim of this work is to determine the mechanisms by which melatonin, a hormone produced in the brain by the pineal gland, inhibits the catalytic activity of EPO. EXPERIMENTAL APPROACH: We utilized H2O2-selective electrode and direct rapid kinetic measurements to determine the pathways by which melatonin inhibits human EPO. KEY RESULTS: In the presence of plasma levels of bromide (Br-), melatonin inactivates EPO at two different points in the classic peroxidase cycle. First, it binds to EPO and forms an inactive complex, melatonin-EPO-Br, which restricts access of H2O2 to the catalytic site of the oxidation enzyme. Second, melatonin competes with Br- and switches the reaction from a two electron (2e-) to a one electron (1e-) pathway allowing the enzyme to function with catalase-like activity. Melatonin is a bulky molecule and binds to the entrance of the EPO haem pocket (regulatory sites). Furthermore, Br- seems to enhance the affinity of this binding. In the absence of Br-, melatonin accelerated formation of EPO Compound II and its decay by serving as a 1e- substrate for EPO Compounds I and II. CONCLUSIONS AND IMPLICATIONS: The interplay between EPO and melatonin may have a broader implication in the function of several biological systems. This dual regulation by melatonin is unique and represents a new mechanism for melatonin to control EPO and its downstream inflammatory pathways.


Subject(s)
Enzyme Inhibitors , Eosinophil Peroxidase/antagonists & inhibitors , Melatonin/pharmacology , Biotransformation , Bromides/pharmacology , Catalysis , Catalytic Domain , Dimethylformamide/pharmacology , Electrochemistry , Electron Transport/drug effects , Eosinophil Peroxidase/isolation & purification , Humans , Hydrogen Peroxide/chemistry , In Vitro Techniques , Kinetics , Melatonin/metabolism , Spectrophotometry, Ultraviolet
2.
J Autoimmun ; 29(2-3): 78-86, 2007.
Article in English | MEDLINE | ID: mdl-17544621

ABSTRACT

There has been a relative paucity of effort at defining effector mechanisms of biliary damage in PBC. We hypothesize that biliary cells are destroyed secondary to the immunologic relationships of inflammation and biliary epithelial apoptosis and, in particular, that biliary damage is a result of reduced levels of glutathione-S-transferase (GST), the production of hypochlorous acid (HOCl) and its association with eosinophil peroxidase (EPO). To address this issue, we examined the expression of EPO and GST in PBC and control livers and demonstrated an increase of EPO within the portal areas of PBC. We also demonstrated that macrophages have evidence of phagocytosed EPO. Furthermore, we studied the influence of HOCl on apoptosis in cultured human biliary epithelial cells (BEC) as well as the associated activity of Bcl-2, Bax, p-JNK, JNK, p53, Fas and caspase-3. HOC1-induced apoptosis in BEC in a dose-dependent fashion increased the activity of caspase-3 and the expression of p53 and p-JNK. Pretreatment with l-buthionine-(S,R)-sulfoximine, a glutathione (GSH) inhibitor, potentiated the sensitivity of BEC to HOCl-induced apoptosis. We conclude that intracellular GSH reduction leads directly to BEC apoptosis. Modulation of these events will be critical to reduce immune-mediated destruction.


Subject(s)
Apoptosis , Bile Ducts/pathology , Eosinophil Peroxidase/metabolism , Liver Cirrhosis, Biliary/metabolism , Liver/metabolism , Oxidative Stress , Bile Ducts/metabolism , Caspase 3/metabolism , Cells, Cultured , Eosinophil Peroxidase/immunology , Eosinophil Peroxidase/isolation & purification , Glutathione/metabolism , Humans , Hypochlorous Acid/pharmacology , Liver/immunology , Liver/pathology , Liver Cirrhosis, Biliary/immunology , Liver Cirrhosis, Biliary/pathology , MAP Kinase Kinase 4/metabolism , Tumor Suppressor Protein p53/metabolism
3.
Biochem J ; 395(2): 295-301, 2006 Apr 15.
Article in English | MEDLINE | ID: mdl-16396635

ABSTRACT

A Pichia pastoris expression system has for the first time been successfully developed to produce rhEPO (recombinant human eosinophil peroxidase). The full-length rhEPO coding sequence was cloned into the pPIC9 vector in frame with the yeast alpha-Factor secretion signal under the transcriptional control of the AOX (acyl-CoA oxidase) promoter, and transformed into P. pastoris strain GS115. Evidence for the production of rhEPO by P. pastoris as a glycosylated dimer precursor of approx. 80 kDa was determined by SDS/PAGE and gel filtration chromatography. Recombinant hEPO undergoes proteolytic processing, similar to that in the native host, to generate two chains of approx. 50 and 20 kDa. A preliminary biochemical characterization of purified rhEPO demonstrated that the spectral and kinetic properties of the recombinant wild-type EPO are comparable with those of the native enzyme and are accompanied by oxidizing activity towards several physiological anionic substrates such as SCN-, Br- and Cl-. On the basis of the estimated K(m) and kcat values it is evident that the pseudohalide SCN- is the most specific substrate for rhEPO, consistent with the catalytic properties of other mammalian EPOs purified from blood.


Subject(s)
Eosinophil Peroxidase/genetics , Eosinophil Peroxidase/metabolism , Gene Expression/genetics , Pichia/genetics , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Animals , Biological Assay , Chromatography, Gel , Chromatography, Ion Exchange , Eosinophil Peroxidase/biosynthesis , Eosinophil Peroxidase/isolation & purification , Humans , Kinetics , Molecular Weight , Recombinant Proteins/biosynthesis , Recombinant Proteins/isolation & purification , Spectrum Analysis , Substrate Specificity , Swine
4.
J Immunol Methods ; 307(1-2): 54-61, 2005 Dec 20.
Article in English | MEDLINE | ID: mdl-16257006

ABSTRACT

Eosinophil granules contain several toxic cationic proteins that contribute to the pathophysiology of allergic diseases. These include eosinophil peroxidase, two ribonucleases, and two forms of the major basic protein (MBP). Extraction of eosinophil granules by exposure to acid solution and fractionation on Sephadex G-50 characteristically yields a distinctive profile of three discrete peaks, and these proteins are usually recovered in good quantities, except for the eosinophil major basic protein homolog (MBP2). We investigated the effect of multiple granule extractions by dilute HCl on the recovery of granule proteins. Isolated granules were repetitively extracted, up to 31 times, in 0.01 M HCl, and the extracts fractionated on Sephadex G-50. Whereas initial extracts yielded the characteristic three-peak fractionation pattern, later extracts yielded four discrete peaks. Characterization of the novel fourth peak showed that it contained MBP2. These results indicate that repetitive extraction of eosinophil granules yields an increased amount of all granule proteins, and that MBP2 can now be recovered in good quantities and in a relatively pure form.


Subject(s)
Eosinophil Granule Proteins/isolation & purification , Eosinophils/chemistry , Blood Proteins/isolation & purification , Cell Fractionation , Cell Separation , Chromatography, Gel , Cytoplasmic Granules/chemistry , Electrophoresis, Polyacrylamide Gel , Eosinophil Cationic Protein/isolation & purification , Eosinophil Major Basic Protein , Eosinophil Peroxidase/isolation & purification , Eosinophil-Derived Neurotoxin/isolation & purification , Eosinophilia/blood , Eosinophils/cytology , Flavins/chemistry , Humans , Immunoassay , Luminescent Measurements , Proteoglycans/isolation & purification , Spectrometry, Fluorescence
SELECTION OF CITATIONS
SEARCH DETAIL
...